Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Legend Biotech Corp

Healthcare US LEGN

35.98USD
-0.3(0.83%)

Last update at 2026-06-03T20:25:00Z

Day Range

34.3537.50
LowHigh

52 Week Range

39.1377.32
LowHigh

Fundamentals

  • Previous Close 36.28
  • Market Cap7597.56M
  • Volume4081530
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-425.37501M
  • Revenue TTM342.80M
  • Revenue Per Share TTM1.90
  • Gross Profit TTM -284.00600M
  • Diluted EPS TTM-2.6

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -445.72400M -386.20800M -307.62200M -130.37000M -1.61600M
Minority interest - - - - -
Net income -446.34900M -386.20900M -303.47700M -132.97200M -2.78400M
Selling general administrative 80.63M 46.94M 23.15M 6.75M 2.77M
Selling and marketing expenses 93.42M 102.54M 49.57M 25.62M 1.16M
Gross profit 51.64M 89.79M 75.68M 57.26M 49.13M
Reconciled depreciation 18.39M 13.92M 9.93M 5.26M 1.68M
Ebit -455.82800M -393.02500M -313.34600M -130.87100M -8.86000M
Ebitda -437.43600M -379.10800M -303.41300M -125.60900M -7.17700M
Depreciation and amortization 18.39M 13.92M 9.93M 5.26M 1.68M
Non operating income net other - - - - -
Operating income -455.82800M -393.02500M -313.34600M -130.87100M -1.53400M
Other operating expenses 575.06M 462.83M 304.88M 192.63M 64.20M
Interest expense 10.80M 0.90M 4.21M 0.22M 0.08M
Tax provision 0.62M 0.00100M -4.14500M 2.60M 1.17M
Interest income 8.18M 0.97M 2.93M 4.58M 6.21M
Net interest income -10.79600M -0.90000M -4.20900M 4.36M 6.13M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.62M 0.00100M -4.14500M 2.60M 1.17M
Total revenue 117.00M 89.79M 75.68M 57.26M 49.13M
Total operating expenses 509.70M 462.83M 304.88M 192.63M 64.20M
Cost of revenue 65.36M - - - -
Total other income expense net 10.10M 6.82M 5.72M 0.50M 7.32M
Discontinued operations - - - - -
Net income from continuing ops -446.34900M -386.20900M -303.47700M -132.97200M -2.78400M
Net income applicable to common shares -446.34900M -386.20900M -303.47700M -132.97200M -2.78400M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1848.61M 1330.96M 1118.37M 721.01M 287.71M
Intangible assets 155.28M 3.41M 4.68M 7.70M 5.15M
Earning assets - - - - -
Other current assets 12.23M 1099.09M 1.44M 580.67M 11.27M
Total liab 589.93M 586.65M 647.16M 440.75M 410.58M
Total stockholder equity 1251.37M 744.31M 471.21M 280.25M -122.86900M
Deferred long term liab - - - - -
Other current liab 140.07M 260.88M 211.36M 99.17M 70.85M
Common stock 0.04M 0.03M 0.03M 0.03M 0.02M
Capital stock 0.04M 0.03M 0.03M 0.03M 0.02M
Retained earnings -1484.71000M -966.45600M -816.96800M -430.75900M -127.28200M
Other liab - 7.89M 244.84M 277.68M 277.76M
Good will - - - -4.85100M -
Other assets 0.00000M 67.68M 7.32M 4.20M 0.67M
Cash 1278.07M 786.03M 688.94M 455.69M 83.36M
Cash and equivalents - - - - -
Total current liabilities 216.42M 297.79M 280.27M 161.17M 127.76M
Current deferred revenue 53.01M 0.45M 60.95M 55.30M 46.29M
Net debt -949.39800M -501.49700M -565.97200M -452.31600M -77.27900M
Short term debt 3.17M 3.56M 0.91M 1.46M 1.03M
Short long term debt - - - - -
Short long term debt total 328.67M 284.53M 122.97M 3.37M 6.08M
Other stockholder equity 2637.12M 744.31M 816.97M 430.76M 0.48M
Property plant equipment - 160.76M 152.91M 121.10M 79.43M
Total current assets 1497.80M 1099.12M 948.75M 592.86M 207.10M
Long term investments 4.36M 0.00000M 4.71M - -
Net tangible assets - 740.90M 466.52M 277.40M -123.38800M
Short term investments 31.00M 239.62M 193.46M 50.00M 75.56M
Net receivables 157.06M 0.09M 63.16M 84.98M 35.76M
Long term debt 281.33M 260.93M 120.46M - -
Inventory 19.43M 10.35M 1.75M 1.80M 1.16M
Accounts payable 20.16M 32.89M 7.04M 5.24M 9.59M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 98.92M 744.28M 471.18M 280.23M -122.88900M
Additional paid in capital - - - - -
Common stock total equity - - - 0.03M 0.02M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 152.42M 66.76M 5.15M 3.97M 0.67M
Deferred long term asset charges - - - - -
Non current assets total 350.81M 231.84M 169.62M 128.15M 80.61M
Capital lease obligations 47.34M 23.60M 2.50M 3.37M 6.08M
Long term debt total - - - - 5.08M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -78.34400M -194.98300M 25.56M -58.65200M -102.25600M
Change to liabilities 32.03M -20.42500M 4.13M 28.48M 96.42M
Total cashflows from investing activities -77.09200M -194.98300M -24.16900M -58.65200M -102.25600M
Net borrowings -2.59600M -1.41900M -2.60600M 14.67M 2.50M
Total cash from financing activities 377.98M 626.66M 618.88M 14.67M 2.50M
Change to operating activities 118.75M 136.73M 20.05M 27.80M 15.80M
Net income -445.72400M -386.20800M -307.62200M -130.37000M -1.61600M
Change in cash 97.09M 233.25M 372.32M -126.80200M 208.05M
Begin period cash flow 688.94M 455.69M 83.36M 210.17M 2.12M
End period cash flow 786.03M 688.94M 455.69M 83.36M 210.17M
Total cash from operating activities -200.02900M -198.46500M -223.00500M -83.06500M 307.68M
Issuance of capital stock 377.64M 623.44M 622.53M - 0.00000M
Depreciation 18.39M 13.92M 9.93M 5.26M 1.68M
Other cashflows from investing activities -13.45300M -194.98300M 0.05M 49.99M -75.25500M
Dividends paid - - - - -
Change to inventory -8.60500M 0.05M -0.64300M -0.02200M -1.12400M
Change to account receivables 50.32M 24.59M -45.00000M -3.77100M 207.61M
Sale purchase of stock - - - - -
Other cashflows from financing activities 2.93M 4.64M 159.40M 22.59M 2.72M
Change to netincome 34.18M 187.74M 92.00M -7.83800M -9.92400M
Capital expenditures 22.27M 47.11M 49.78M 39.17M 21.02M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 186.32M 140.87M -23.91600M 52.48M 318.71M
Stock based compensation 34.34M 20.16M 4.76M 1.27M 0.70M
Other non cash items 6.65M 187.74M 84.62M -4.35800M -6.13200M
Free cash flow -222.30400M -245.57700M -272.78100M -122.23500M 286.66M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
LEGN
Legend Biotech Corp		 -0.3 0.83% 35.98 - - 33.76 7.69 30.32 -18.0941
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.38 0.89% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Legend Biotech Corp

2101 Cottontail Lane, Somerset, NJ, United States, 08873

Key Executives

Name Title Year Born
Dr. Ying Huang Ph.D. CEO & Director 1973
Ms. Lori A. Macomber CPA Chief Financial Officer NA
Joanne Choi Sr. Mang. of Investor Relations NA
Mr. Marc Harrison VP & Gen. Counsel NA
Deborah Wong Exec. Director of Strategic Marketing & Corp. Communications NA
Ms. Liz Gosen Sr. VP of Global Technical Operations NA
Dr. Yuhong Qiu Ph.D. Sr. VP of Global Regulatory Affairs NA
Dr. Guowei Fang Ph.D. Sr. VP & Global Head of Research and Early Devel. NA
Mr. Steven J. Gavel Sr. VP of Commercial Devel., US & Europe NA
Mr. Alan Kick Sr. VP of Global Quality NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.